Background: Several authors pointed out that in the next decades dementia will affect a considerably increasing number of the elderly. The question was raised if life-expectancy was projected to conservative, resulting in revisions with higher life-expectancy and larger numbers of the oldest population. The present paper analyses the influence of such revisions on the future numbers of dementia sufferers in Austria.
Subjects And Methods: For this purpose we used meta-analyses of epidemiological studies and the population projections for the period until 2050 of the Austrian Bureau of Statistics as well as of the United Nations Population Division of the year 2001 as well of the year 2005.
Results: Using the extrapolations of the Austrian Bureau of Statistics of the year 1999 as well as of the United Nations Population Division of the year 2001, the number of dementia cases in Austria in the year 2050 will rise to about 233 thousands. According to the four years later performed extrapolations of the United Nations Population Division of the year 2005, dementia cases in Austria will raise to about 262 thousands in the year 2050.
Conclusions: In the next decades, the number of persons suffering from dementia will rise considerably. Increasing life-expectancy will result in markedly higher numbers of persons with dementia than estimated from earlier population projections. Nevertheless, this is the first analysis of future dementia cases based on projections from two different dates, but using the same source. We must conclude that the dramatically increasing number of dementia cases requires comprehensive planning of the health and social care system.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Correlations between Volume Loss of Temporal and Subcortical Functional Subregions and Cognitive Impairment at Various Stages of Cognitive Decline.
J Integr Neurosci
December 2024
Department of Radiology, Affiliated Hospital of North Sichuan Medical College, 637000 Nanchong, Sichuan, China.
Background: The relationship between subregion atrophy in the entire temporal lobe and subcortical nuclei and cognitive decline at various stages of Alzheimer's disease (AD) is unclear.
Methods: We selected 711 participants from the AD Neuroimaging Initiative (ADNI) database, which included 195 cases of cognitively normal (CN), 271 cases of early Mild cognitive impairment (MCI) (EMCI), 132 cases of late MCI (LMCI), and 113 cases of AD. we looked at how subregion atrophy in the temporal lobe and subcortical nuclei correlated with cognition at different stages of AD.
Recombinant zoster vaccine and the risk of dementia.
Vaccine
December 2024
F.I. Proctor Foundation, University of California, San Francisco, California, United States; Department of Ophthalmology, University of California, San Francisco, California, United States; Department of Epidemiology and Biostatistics, University of California, San Francisco, California, United States. Electronic address:
Background: Herpes zoster is a potential risk factor for dementia. The effectiveness of the recombinant zoster vaccine for preventing dementia is uncertain.
Methods: This retrospective cohort study used de-identified claims data from the Optum Labs Data Warehouse database from January 1, 2017, to December 31, 2022, to determine whether the recombinant zoster vaccine is associated with a reduced risk of dementia.
Longitudinal associations between air pollution and incident dementia as mediated by MRI-measured brain volumes in the UK Biobank.
Environ Int
December 2024
MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK; National Institute for Health Research Health Protection Research Unit in Chemical and Radiation Threats and Hazards, School of Public Health, Imperial College London, UK. Electronic address:
Background: Although there is increasing evidence that environmental exposures are associated with the risk of neurodegenerative conditions, there is still limited mechanistic evidence evaluating potential mediators in human populations.
Methods: UK Biobank is a large long-term study of 500,000 adults enrolled from 2006 to 2010 age 40-69 years. ICD-10 classified reports of dementia cases up to 2022 (Alzheimer's disease, vascular dementia, dementia in other classified diseases, and unspecified dementia) were identified from health record linkage.
[Modern aspects of chronic cerebral ischemia pathogenetic therapy].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
S.D. Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan.
Chronic cerebral ischemia (CCI) is one of the most common forms of cerebrovascular disease, which affects a significant number of patients, often leading to disability, cognitive impairment and dementia. The analysis of modern data on the pathogenesis and risk factors for the development of CCI, as well as on the mechanisms of action of Mexidol on various links in the pathogenesis of CCI. A systematic search was conducted in the PubMed, MEDLINE and Google Scholar databases, on Russian and English-language sites with open access publications on the problem of CCI and on the drug Mexidol in the period from 2014 to 2024.
View Article and Find Full Text PDFDeoxyvasicinone hybrids in the management of Alzheimer's disease: Recent advances on manmade derivatives, pharmacological activities, and structure-activity relationship.
Arch Pharm (Weinheim)
January 2025
Department of Pharmacognosy, University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
Alzheimer's disease (AD) is a prevalent neurological illness that affects over 80% of aged adults globally in cases of dementia. Although the exact pathophysiological causes of AD remain unclear, its pathogenesis is primarily driven by several distinct biochemical alterations: (i) the accumulation of toxic Aβ plaques, (ii) the hyperphosphorylation of tau proteins, (iii) oxidative stress resulting in cell death, and (iv) an imbalance between the two main neurotransmitters, glutamate and acetylcholine (ACh). Currently, there are very few medications available and no treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!